The most prevalent breast cancer subtype is the hormone receptor-positive (HR+) subtype, which is highly treatable in its early stages; however, the risk of disease relapse remains steady from 5 to more than 20 years after diagnosis [75] As a matter of fact, most of the HR+ patients who present distant metastases do so after the first 5 years as a result of undetected residual disease [76]. This evidence concerns the gene NR4A1 and breast carcinoma.